With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.
62937-45-5, A solution of 5-(4-chlorophenyl)-2-{ [l-(4-chloropyridin-3-yl) H-l,2,4-triazol-3-yl]methyl}-4- [(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-l,2,4-triazol-3-one (Example 6A, 150 mg, 300 muiotaetaomicron) in ethanol (600 mu) was treated with D-prolinamide (342 mg, 3.00 mmol) and heated at reflux overnight. The reaction mixture was purified by preparative HPLC (Method 4) affording 137 mg (79 % of th.) of the title compound. LC-MS (Method 2): Rt = 1.03 min; MS (ESIpos): m/z = 578.2 [M+H]+ -NMR (400 MHz, DMSO-d6) delta [ppm]: 8.73 (s, 1H), 8.27-8.00 (m, 2H), 7.80-7.50 (m, 4H), 7.30 (s, 1H), 7.10 (s, 1H), 6.91 (d, 1H), 6.52 (d, 1H), 5.19-4.99 (m, 2H), 4.40-4.20 (br m, 1H), 4.16-3.76 (m, 3H), 2.93-2.66 (m, 2H), 2.11-1.91 (m, 1H), 1.85-1.44 (m, 3H).
The synthetic route of 62937-45-5 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGESELLSCHAFT; COLLIN-KROePELIN, Marie-Pierre; KOLKHOF, Peter; NEUBAUER, Thomas; FUeRSTNER, Chantal; POOK, Elisabeth; WITTWER, Matthias, Beat; LUSTIG, Klemens; TINEL, Hanna; LINDNER, Niels; SCHIRMER, Heiko; (449 pag.)WO2019/81307; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI